Abstracts Archive - Page 817 of 1683 - ATC Abstracts

2018 American Transplant Congress
The LncRNA MALAT1 Induces Tolerogenic DCs and Antigen Specific Tregs Subsequently Mediating Cardiac Allograft Tolerance in Mice via MiR-155/DC-SIGN/IL10 Axis
M. Zhang,^1,2 J. Wu,^1,2 H. Zhang,^1,2 M. Liu,^1,2 Y. Zheng,^1,2 X. Jin,^1,2 S. Li,^1,2 Q. Zhao,^1,2 X. Liu,^1,2 Y. Sun,^1,2 B. Yu.^1,2
¹Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China; ²The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry of Education, Harbin, Heilongjiang, China.
Background: Tolerogenic dendritic cells(DCs) by shaping T cells immunity and inducing Tregs play critical roles in the induction of allograft tolerance in transplantation. Long noncoding…
2018 American Transplant Congress
Loss of HIF-1α in CD4 T Cell Improve Outcome of Mouse Vascularized Osteomyocutaneous Allotransplantation under Costimulation Blockade
C-.H. Lin,^1,2 M. Anggelia,^1,2 H. Yang,³ W. Chuang,⁴ H. Cheng,¹ F-.C. Wei,^1,2 G. Brandacher.⁵
¹PRS, Center for VCA, Chang Gung Memorial Hospital, Taoyuan, Taiwan; ²Chang Gung Medical College and Chang Gung University, Taoyuan, Taiwan; ³Nephrology, Chang Gung Memorial Hospital, Taoyuan, Taiwan; ⁴Pathology, Chang Gung Memorial Hospital, Taoyuan, Taiwan; ⁵PRS, Johns Hopkins University School of Medicine, Baltimore, MD.
Background: Allograft survival depends on the balance of effector T cells (Teff) and regulatory T cells (Tregs). Previous study suggested that the balance is controlled…
2018 American Transplant Congress
Umbilical Cords-Derived Mesenchymal Stem Cells Ameliorates Hepatic Ischemia-Reperfusion Injury via Activating the AMPK-mTOR/ULK1 Signaling Pathway Enhanced Autophagy
J. Zheng,^1,2 J. Cai,^1,2 L. Chen,^1,2 J. Yao,^1,2 K. Zeng,^1,2 H. Li,^1,2 Y. Zhang,^1,2 Y. Yang.^1,2
¹Department of Hepatic Surgery and Liver Transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Guangzhou, Guangdong, China; ²Guangdong Key Laboratory of Liver Disease Research, Key Laboratory of Liver Disease Biotherapy and Translational Medicine of Guangdong Higher Education Institutes, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, .
UC-MSCs induction of anti-apoptosis has been indicated to play protective roles in liver ischemia-reperfusion (I/R) model. However, the exact molecular mechanisms of UC-MSCs in hepatic…
2018 American Transplant Congress
Low Intensity Conditioning Protocol for Inducing Chimerism-Based Tolerance in Non-Obese Diabetic Mice
A. Chhabra, Y. Huang, H. Xu, A. Merchak, S. Ildstad.
Institute for Cellular Therapeutics, University of Louisville, Louisville, KY.
Type 1 diabetes is the most common chronic disease affecting children. Islet cell or pancreas transplantation offer the most physiologic approach to glucose homostasis. However…
2018 American Transplant Congress
The Relative Immunogenicity of HLA Mismatches in Adult Liver Transplant Recipients
V. Jucaud,¹ A. Shaked,² M. DesMarais,³ P. Sayre,³ M. Everly.¹
¹Terasaki Research Institute, Los Angeles, CA; ²University of Pennsylvania, Philadelphia, PA; ³Immune Tolerance Network, Seattle, WA.
Determining the immunogenicity of HLA mismatches (MM) may help preventing the appearance of de novo DSA (dnDSA) and avoiding antibody-mediated injuries.We studied the development of…
2018 American Transplant Congress
Genome-Wide Association Study Assessing Risk of Rejection in Pediatric Transplant Recipients
T. Papaz,¹ S. Min,¹ O. Lee,¹ T. Blydt-Hansen,³ U. Allen,¹ Y. Avitzur,¹ P. Birk,² B. Foster,⁴ H. Grasemann,¹ L. Hamiwka,⁵ R. Parekh,¹ V. Phan,⁶ S. Urschel,⁷ S. Mital.¹
¹SickKids Hospital, Toronto, ON, Canada; ²Winnipeg Children's Hospital, Winnipeg, MB, Canada; ³BC Children's Hospital, Vancouver, BC, Canada; ⁴Montreal Children's Hospital, Montreal, QC, Canada; ⁵Alberta Children's Hospital, Calgary, AB, Canada; ⁶CHU Sainte Justines, Montreal, QC, Canada; ⁷Stollery Children's Hospital, Edmonton, AB, Canada.
Background: Rejection risk varies after solid organ transplantation (SOT). We explored genomic variants associated with susceptibility to graft rejection.Methods: SOTs enrolled in a multicenter prospective…
2018 American Transplant Congress
Genome-Wide Association Study of Tacrolimus Dose in Pediatric Solid Organ Transplant Recipients in the CNTRP POSITIVE Study
S. Min,¹ T. Papaz,¹ T. Blydt-Hansen,³ O. Lee,¹ U. Allen,¹ P. Birk,² H. Grasemann,¹ L. Hamiwka,⁴ C. Litalien,⁵ V. Ng,¹ R. Parekh,¹ K. Tinckam,⁶ S. Urschel,⁷ B. Foster,⁸ S. Mital.¹
¹The Hospital for Sick Children, Toronto, Canada; ²Winnipeg Children's Hospital, Winnipeg, Canada; ³BC Children's Hospital, Vancouver, Canada; ⁴Alberta Children's Hospital, Calgary, Canada; ⁵CHU Ste-Justine, Montreal, Canada; ⁶University Health Network, Toronto, Canada; ⁷Stollery Children's Hospital, Edmonton, Canada; ⁸Montreal Children's Hospital, Montreal, Canada.
PURPOSE: There are significant challenges in achieving therapeutic tacrolimus (Tac) concentrations after transplant. We explored variants associated with tacrolimus dose requirements in pediatric solid organ…
2018 American Transplant Congress
Reduction in Circulating CD19⁺CD24⁺CD27⁺ Regulatory B Cell Frequency Predicts Acute Rejection in Liver Transplant Patients
H. Zhou, Z. Rao, Y. Lu, J. Rao, J. Gu, L. Lu, Y. Xia.
Liver Transplant Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background: Accumulating evidence suggests that regulatory B cells (Bregs) play an important role in modulating inflammation and autoimmune diseases. However, whether Bregs regulate acute liver…
2018 American Transplant Congress
Association between Everolimus Trough Levels, Onset of Related Adverse Events, and Treatment Discontinuation after Liver Transplantation: 24-Month Results from the H2304 Study
J. Fung,¹ F. Saliba,¹ H. Schlitt,¹ G. Junge,² K. McCague,³ D. Patel,³ M. Charlton.¹
¹H2304 Study Group, Chicago; ²Novartis Pharma AG, Basel, Switzerland; ³Novartis Pharmaceuticals Corporation, East Hanover.
Purpose: Evaluation of mammalian target of rapamycin inhibitor (mTORi)-related adverse events (AEs) and drug trough levels (C0) at onset may aid their management in liver…
2018 American Transplant Congress
Post-Hoc Analysis of Everolimus Trough Levels around the Onset of Related Adverse Events and Treatment Discontinuation in De Novo Kidney Transplant Recipients from the US92 Study
F. Shihab,¹ Y. Qazi,¹ V. Peddi,¹ D. Shaffer,¹ K. McCague,² D. Patel,² S. Mulgaonkar.¹
¹US92 Study Group, Salt Lake City; ²Novartis Pharmaceutical Corporation, East Hanover.
Purpose: Around 30%-50% of kidney transplant recipients (KTR) on sirolimus discontinue treatment due to drug-related adverse events (AE) and ~23% on everolimus (EVR) discontinue treatment…